NasdaqCM - Delayed Quote USD

RedHill Biopharma Ltd. (RDHL)

0.4637 +0.0054 (+1.18%)
At close: May 13 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,530.0000
6,530.0000
61,800.0000
85,757.0000
64,359.0000
Cost of Revenue
3,459.0000
3,459.0000
33,337.0000
49,406.0000
36,892.0000
Gross Profit
3,071.0000
3,071.0000
28,463.0000
36,351.0000
27,467.0000
Operating Expense
34,503.0000
34,503.0000
71,307.0000
117,486.0000
91,151.0000
Operating Income
-31,432.0000
-31,432.0000
-42,844.0000
-81,135.0000
-63,684.0000
Net Non Operating Interest Income Expense
-2,158.0000
-2,158.0000
-42,207.0000
-16,581.0000
-12,574.0000
Other Income Expense
57,542.0000
57,542.0000
13,382.0000
-28.0000
85.0000
Pretax Income
23,952.0000
23,952.0000
-71,669.0000
-97,744.0000
-76,173.0000
Net Income Common Stockholders
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Diluted NI Available to Com Stockholders
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Basic EPS
4.00
4.00
-48.00
-84.00
-79.35
Diluted EPS
4.00
4.00
-48.00
-84.00
-79.35
Basic Average Shares
6,478.0550
6,478.0550
1,540.7480
1,163.1820
959.9540
Diluted Average Shares
6,478.0550
6,478.0550
1,540.7480
1,163.1820
959.9540
Total Operating Income as Reported
12,632.0000
12,632.0000
-42,844.0000
-81,135.0000
-63,684.0000
Total Expenses
37,962.0000
37,962.0000
104,644.0000
166,892.0000
128,043.0000
Net Income from Continuing & Discontinued Operation
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Normalized Income
-13,769.3400
-13,769.3400
-85,051.0000
-97,716.0000
-76,258.0000
Interest Income
94.0000
94.0000
140.0000
51.0000
176.0000
Interest Expense
367.0000
367.0000
41,333.0000
16,567.0000
12,450.0000
Net Interest Income
-2,158.0000
-2,158.0000
-42,207.0000
-16,581.0000
-12,574.0000
EBIT
24,319.0000
24,319.0000
-30,336.0000
-81,177.0000
-63,723.0000
EBITDA
26,309.0000
26,309.0000
-22,182.0000
-63,028.0000
-54,978.0000
Reconciled Cost of Revenue
3,459.0000
3,459.0000
33,337.0000
49,406.0000
36,892.0000
Reconciled Depreciation
1,990.0000
1,990.0000
8,154.0000
18,149.0000
8,745.0000
Net Income from Continuing Operation Net Minority Interest
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Total Unusual Items Excluding Goodwill
48,942.0000
48,942.0000
13,382.0000
-28.0000
85.0000
Total Unusual Items
48,942.0000
48,942.0000
13,382.0000
-28.0000
85.0000
Normalized EBITDA
-22,633.0000
-22,633.0000
-35,564.0000
-63,000.0000
-55,063.0000
Tax Rate for Calcs
0.0002
0.0002
--
--
--
Tax Effect of Unusual Items
11,256.6600
11,256.6600
--
--
--
12/31/2020 - 1/7/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KMDA Kamada Ltd.
5.57
+0.72%
 
SBFM Sunshine Biopharma, Inc.
0.8711
-2.40%
 
AKAN Akanda Corp.
0.0926
-5.70%
 
SBFMW Sunshine Biopharma, Inc.
0.1700
+21.17%
 
OPTN OptiNose, Inc.
1.1700
-4.10%
 
IMCC IM Cannabis Corp.
0.7091
+4.65%
 
EBS Emergent BioSolutions Inc.
5.36
+23.22%
 
SXTC China SXT Pharmaceuticals, Inc.
1.0400
-1.89%
 
BFRI Biofrontera Inc.
1.1700
-7.14%
 
ALKS Alkermes plc
24.71
+2.74%